NASDAQ:ALNY

Alnylam Pharmaceuticals Stock Insider Trading

etoro logo Buy ALNY
*Your capital is at risk
$286.12
-9.51 (-3.22%)
At Close: Jun 02, 2026

Alnylam Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -64.22. In total, the insiders bought 59.77K and sold 20.65K ALNY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-64.22
Buy 59.77K shares
Sell 20.65K shares
24% Buy Activity
Weak Negative Correlation
Buy Signal Low Confidence
Mar 02, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -64.22.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Mar 04, 2026
Sell
Common Stock
S-Sale
Garg Pushkal
EVP Chief R&d
Officer 215
Value: $69.0K
Mar 04, 2026
Sell
Common Stock
S-Sale
Garg Pushkal
EVP Chief R&d
Officer 767
Value: $248.4K
Mar 04, 2026
Sell
Common Stock
S-Sale
Poulton Jeffrey V.
EVP, Chief Financial Officer
C-Suite Officer 114
Value: $36.4K
Mar 04, 2026
Sell
Common Stock
S-Sale
Poulton Jeffrey V.
EVP, Chief Financial Officer
C-Suite Officer 818
Value: $264.9K
Mar 04, 2026
Sell
Common Stock
S-Sale
Greenstreet Yvonne
Chief Executive Officer
CEO / President 444
Value: $143.4K
Mar 04, 2026
Sell
Common Stock
S-Sale
Tanguler Tolga
EVP, Chief Commercial Officer
Officer 767
Value: $248.4K
Mar 04, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 28
Value: $9K
Mar 04, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 75
Value: $24.4K
Mar 04, 2026
Sell
Common Stock
S-Sale
Greenstreet Yvonne
Chief Executive Officer
CEO / President 973
Value: $315.1K
Mar 03, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 289
Value: $91.5K
Mar 03, 2026
Sell
Common Stock
S-Sale
Garg Pushkal
EVP Chief R&d
Officer 317
Value: $101.1K
Mar 03, 2026
Sell
Common Stock
S-Sale
Garg Pushkal
EVP Chief R&d
Officer 355
Value: $112.4K
Mar 03, 2026
Sell
Common Stock
S-Sale
Garg Pushkal
EVP Chief R&d
Officer 463
Value: $148.9K
Mar 02, 2026
Buy
Common Stock
A-Award
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 3 688
Value: $1.20M
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 47
Value: $15.2K
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 258
Value: $84.0K
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 392
Value: $128.1K
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 329
Value: $107.8K
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 100
Value: $32.9K
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 81
Value: $26.8K
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 94
Value: $31.2K
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 37
Value: $12.3K
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 170
Value: $56.1K
Mar 02, 2026
Sell
Common Stock
S-Sale
Fitzgerald Kevin Joseph
Cso & EVP, Head Of Research
Officer 90
Value: $29.2K
Mar 02, 2026
Buy
Stock Option (right to buy)
A-Award
Garg Pushkal
EVP Chief R&d
Officer 10 480
Value: $3.41M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ALNYLAM PHARMACEUTICALS
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE